Loading...

Won Kim, MD

TitleAssistant Professor
SchoolUCSF School of Medicine
DepartmentMedicine
Phone415-353-7171
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    The Cooper Union for the Advancement of Science and ArtMD2003Engineering
    Weill Cornell Medicine CollegeMD2007Medicine

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Global Health

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, Speers C, Cooperberg MR, Kim W, Ryan CJ, Den RB, Freedland SJ, Posadas E, Sandler H, Klein EA, Black P, Seiler R, Tomlins SA, Chinnaiyan AM, Jenkins RB, Davicioni E, Ross AE, Schaeffer EM, Nguyen PL, Carroll PR, Karnes RJ, Spratt DE, Feng FY. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncol. 2017 May 11. PMID: 28494073.
      View in: PubMed
    2. Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard CC, Thomas GV, Tomlins SA, Knudsen KE, Lord CJ, Ryan CJ, Youngren J, Beer TM, Ashworth A, Small EJ, Feng FY. Analysis of Circulating Cell-free DNA Identifies Multi-clonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer Discov. 2017 Apr 27. PMID: 28450426.
      View in: PubMed
    3. Wei XX, Hsieh AC, Kim W, Friedlander T, Lin AM, Louttit M, Ryan CJ. A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer. Oncologist. 2017 Mar 17. PMID: 28314838.
      View in: PubMed
    4. Aggarwal R, Bryce A, Ryan CJ, Harzstark A, Derleth C, Kim W, Friedlander T, Lin AM, Rodvelt-Bagchi T, Dhawan M, Zhang L, Lee M, Siebeneck E, Hough J, Small EJ. A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. Urol Oncol. 2017 Feb 01. PMID: 28161323.
      View in: PubMed
    5. Kim W, Fong L. Can Prostate Cancer Really Respond to Immunotherapy? J Clin Oncol. 2017 Jan; 35(1):4-5. PMID: 28034060.
      View in: PubMed
    6. Kim W, Ryan CJ. Use of androgen receptor signaling-targeted therapies in chemotherapy-naive metastatic castration-resistant prostate cancer: a call for patient-centered studies. J Comp Eff Res. 2016 Jan; 5(1):5-7. PMID: 26690748.
      View in: PubMed
    7. Hsieh AC, Nguyen HG, Wen L, Edlind MP, Carroll PR, Kim W, Ruggero D. Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors. Sci Signal. 2015; 8(403):ra116. PMID: 26577921.
      View in: PubMed
    8. Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res. 2014 Dec 15; 20(24):6269-76. PMID: 25336698; PMCID: PMC4277885 [Available on 12/15/15].
    9. Kim W, Ryan CJ. Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies. Cancer. 2015 Feb 1; 121(3):361-71. PMID: 25236176.
      View in: PubMed
    10. Kim W, Jones JO, Diamond M, Haqq C, Molina A, Small EJ, Ryan CJ. Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):292-9. PMID: 25047002.
      View in: PubMed
    11. Kim W, Ryan CJ. Friend or foe: the bifunctional role of steroid hormones in prostate cancer. Oncology (Williston Park). 2014 May; 28(5):408, 410. PMID: 25004655.
      View in: PubMed
    12. Van Allen EM, Foye A, Wagle N, Kim W, Carter SL, McKenna A, Simko JP, Garraway LA, Febbo PG. Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy. Prostate Cancer Prostatic Dis. 2014 Mar; 17(1):23-7. PMID: 24366412; PMCID: PMC4364998.
    13. Kim W, Febbo PG. The current and future role of sequenced-based analysis in prostate cancer tretament. Personalized Medicine. 2013; 10(3):257-273.
    14. Kim W, Febbo PG. RNA transcription and translation. In Stadler WM ed. Cancer Biology Review: A Case-Based Approach. 2013.
    15. Kim W, Ryan CJ. Androgen receptor directed therapies in castration-resistant metastatic prostate cancer. Curr Treat Options Oncol. 2012 Jun; 13(2):189-200. PMID: 22539224.
      View in: PubMed
    16. Gelbman BD, Cham MD, Kim W, Libby DM, Smith JP, Port JL, Altorki NK, Henschke CI, Yankelevitz DF. Radiographic and clinical characterization of false negative results from CT-guided needle biopsies of lung nodules. J Thorac Oncol. 2012 May; 7(5):815-20. PMID: 22729035.
      View in: PubMed
    Won's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP